Targeting neglected kinases for new breast cancer therapies

我们的新公司正在开发治疗乳腺癌和其他类型癌症的新药。我们与领先的大学研究人员合作，利用他们的知识和专业知识来针对以前未解决的癌症易感性。我们正在创造第一种针对癌症特定缺陷的药物，建立在一种经过验证的调节蛋白激酶的策略之上，这是一种以前用于治疗一系列癌症的成功策略。我们的拨款计划将扩大原有的科学基础，发展我们的研究团队和药物开发活动，并通过与其他尖端企业的合作建立我们公司的技能和能力。成功的早期药物开发是资源密集型的，我们的计划是为了确保有价值的专利组合和强大的业务能力。我们正在进行的研究旨在通过有效的规划和实现目标来实现成功，这将扩大我们公司的规模和复杂性。我们计划通过识别和提供新疗法来支持有需要的癌症患者。成功将增加我们的产品价值，使其对进一步投资和与全球制药公司合作具有吸引力。

Our new company is developing novel medicines for breast and other cancer types. We collaborate with leading university researchers, leveraging their knowledge and expertise to target a previously unaddressed cancer susceptibility. We are creating the first medicines tailored to a specific defect in cancer, building on a validated strategy to modulate protein kinases, a previously successful strategy used to treat a range of cancers.Our grant plan will expand on the original scientific foundation, grow our research team and drug development activities, and build our company skillsets and capabilities through partnerships with other cutting-edge businesses.Successful early drug development is resource-intensive, and our plan is built to secure a valuable patent portfolio and robust business capabilities. Our ongoing research is designed to deliver success through efficient planning and aims to achieve goals that will expand the size and sophistication of our company efforts. We plan to support cancer patients in need, through identification and delivery of novel therapies. Success will increase our product value, making it attractive for further investment and collaboration with global pharmaceutical companies.